1. Manufacturer’s comment on possible captopril-induced fetal abnormalities

   Newsletter Article 04 February 2013 Pages: 1 - 1

2. Responsible reporting of adverse reactions is urged

   Newsletter Article 04 February 2013 Pages: 1 - 1

3. A basis for evaluating reports must be established

   Newsletter Article 04 February 2013 Pages: 1 - 2

4. Essential statistical information must be supplied

   Newsletter Article 04 February 2013 Pages: 2 - 2

5. Further comment on digoxin interactions

   Newsletter Article 04 February 2013 Pages: 2 - 2

6. Alprostadil

   Newsletter Article 04 February 2013 Pages: 3 - 3

7. Amiodarone*

   Newsletter Article 04 February 2013 Pages: 3 - 3

8. Benoxaprofen

   Newsletter Article 04 February 2013 Pages: 3 - 3

9. Bromocriptine

   Newsletter Article 04 February 2013 Pages: 3 - 4

10. Carbamazepine interaction

    Newsletter Article 04 February 2013 Pages: 4 - 4

11. Cimetidine

    Newsletter Article 04 February 2013 Pages: 4 - 4

12. Co-trimoxazole

    Newsletter Article 04 February 2013 Pages: 4 - 4

13. Doxepin*

    Newsletter Article 04 February 2013 Pages: 4 - 4

14. Ergometrine

    Newsletter Article 04 February 2013 Pages: 4 - 5

15. Heparin

    Newsletter Article 04 February 2013 Pages: 5 - 5

16. Hydrochlorothiazide

    Newsletter Article 04 February 2013 Pages: 5 - 5

17. Lithium interaction see Carbamazepine

    Newsletter Article 04 February 2013 Pages: 5 - 5

18. Lithium*

    Newsletter Article 04 February 2013 Pages: 5 - 5

19. Methylprednisolone

    Newsletter Article 04 February 2013 Pages: 5 - 6

20. Metrizamide

    Newsletter Article 04 February 2013 Pages: 6 - 6

21. Oxytocin see Ergometrine

    Newsletter Article 04 February 2013 Pages: 6 - 6

22. Perhexiline

    Newsletter Article 04 February 2013 Pages: 6 - 6

23. Phenobarbitone elixir

    Newsletter Article 04 February 2013 Pages: 6 - 6

24. Podophyllin*

    Newsletter Article 04 February 2013 Pages: 6 - 6

25. Potassium citrate mixture

    Newsletter Article 04 February 2013 Pages: 6 - 6

26. Ranitidine*

    Newsletter Article 04 February 2013 Pages: 7 - 7

27. Sodium valproate

    Newsletter Article 04 February 2013 Pages: 7 - 7

28. Sotalol see Hydrochlorothiazide

    Newsletter Article 04 February 2013 Pages: 7 - 7

29. Sulindac*

    Newsletter Article 04 February 2013 Pages: 7 - 7

30. Tetanus toxoid

    Newsletter Article 04 February 2013 Pages: 7 - 7

31. Zomepirac

    Newsletter Article 04 February 2013 Pages: 7 - 7

32. Electrolyte imbalance and renal injury during cisplatin therapy

    Newsletter Article 04 February 2013 Pages: 8 - 8

33. A reappraisal of analgesic nephropathy

    Newsletter Article 04 February 2013 Pages: 8 - 9

34. Some drugs for lowering coronary risks can be harmful

    Newsletter Article 04 February 2013 Pages: 9 - 9

35. Physostigmine for the treatment of phencyclidine intoxication

    Newsletter Article 04 February 2013 Pages: 10 - 10

36. Myopathy as a result of ipecac abuse

    Newsletter Article 04 February 2013 Pages: 10 - 10

37. Acetic acid for carbon monoxide poisoning

    Newsletter Article 04 February 2013 Pages: 10 - 10

38. Acute polyneuropathy following methamidophos poisoning

    Newsletter Article 04 February 2013 Pages: 10 - 11

39. Neurological complications occur after ethylene glycol poisoning

    Newsletter Article 04 February 2013 Pages: 11 - 11

40. Prednisone

    Newsletter Article 04 February 2013 Pages: 11 - 11

41. Prednisolone

    Newsletter Article 04 February 2013 Pages: 11 - 12

42. Minoxidil

    Newsletter Article 04 February 2013 Pages: 12 - 12